Brief: Medigene H1 Revenue Down At EUR 3.7 Million

Medigene AG

07/08/2020 06:34

Aug 7 (Reuters) - MEDIGENE AG  MDG1k.DE :
    * BY END OF 2020, MEDIGENE EXPECTS TO COMPLETE DOSING OF
FIRST
THREE DOSE COHORTS OF PHASE I PART OF PHASE I/II TRIAL OF
MDG1011 IN AML AND MDS.
    * H1 REVENUE GENERATED BY COMPANY DECREASED BY 35% TO
EUR3,673 K
IN REPORTING PERIOD (6M 2019: EUR5,619 K)
    * H1 NEGATIVE EBITDA INCREASED AS EXPECTED DUE TO LOWER
REVENUES
AND SLIGHTLY HIGHER RESEARCH AND DEVELOPMENT COSTS BY 33% IN
PERIOD TO EUR11,325 K (6M 2019 (ADJUSTED): EUR8,532 K).
    * CONFIRMS FINANCIAL GUIDANCE AND CONTINUES TO EXPECT TOTAL
REVENUE OF EUR7-9 M, RESEARCH AND DEVELOPMENT EXPENSES OF
EUR24-29 M AND AN EBITDA LOSS OF EUR19-27 M.

Source text for Eikon:  ID:nPex3W9lga 
Further company coverage:  MDG1k.DE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))